Several anti-tumor therapeutic agents that have been used clinically, including immunotherapeutic agent such as rituximab 16 and genotoxic agents such as cisplatin, etoposide, vincristine 68, can suppress YY1 expression; however, their molecular mechanism in regulating YY1, especially whether they can directly inhibit YY1, remains unclear. Here, YY1 is linked to neoplasm.